TP53 and melanoma: In line with our hypothesis that enoxacin could be targeting MdmX expression in melanoma, we observed a dose-dependent decrease in MdmX protein levels in enoxacin-treated A375 cells, which could explain the detected changes in p53 activity, despite the absence of significant changes in p53 protein levels (Fig 3A, right panel).